S-1: Biofrontera Inc. Files S-1 for Resale of 13.6 Million Shares Following Preferred Stock Conversion and Strategic Ameluz Acquisition

Biofrontera Inc. has filed an S-1 registration statement to allow selling stockholders to resell 13,602,176 shares of common stock issued from the conversion of Series C Convertible Preferred Stock, with the company not receiving any proceeds from these sales.

Summary

• Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on commercializing pharmaceutical products for dermatological conditions, primarily photodynamic therapy (PDT) and topical antibiotics.
• The company's principal licensed product is Ameluz, used in combination with the RhodoLED lamp series for the treatment of actinic keratoses (AK) on the face and scalp, showing up to 91% clearance after one or two treatments with limited scarring.
• The total market size for AK treatments is estimated at $4 billion, with PDT currently representing approximately 2% ($100 million) and cryotherapy dominating at 86%.
• Biofrontera's targeted market for Ameluz PDT is approximately 11% or $500 million of the total AK market, aiming to convert cryotherapy treatments for more than 14 lesions.
• The second licensed product, Xepi, a topical antibiotic for impetigo, has generated limited revenue due to third-party manufacturing delays, and the company decided to divest this product line in Q3 2024, with the transaction anticipated to close in H2 2025.
• On June 30, 2025, Biofrontera entered into an agreement to acquire all U.S. rights to Ameluz and RhodoLED and associated patents from Biofrontera AG, replacing the former 25-35% transfer price model with a new royalty structure of 12% for U.S. Ameluz revenue below $65 million and 15% for revenue exceeding that threshold.
• As part of the acquisition, Biofrontera issued 3,019 shares of Series D Convertible Preferred Stock to Biofrontera AG.
• The company completed a private placement on July 1, 2025, issuing 8,500 shares of Series C Preferred Stock for an aggregate offering price of $8.5 million, with proceeds intended to fund costs assumed pursuant to the Ameluz acquisition.
• As of July 15, 2025, common stock outstanding was 10,138,567 shares, and the last reported sale price per share on the Nasdaq Capital Market (BFRI) was $0.82.
• Assuming the conversion of all Series C Preferred shares offered, the common stock outstanding would increase to 23,740,743 shares.

Sentiment

Score: 6

Explanation: The document presents significant strategic advancements, such as the acquisition of full U.S. Ameluz rights and ongoing clinical development, which are positive for long-term growth. However, these positives are balanced by substantial financial risks, including a 'going concern' doubt, a history of operating losses, potential dilution from various convertible securities, and the impact of patent expirations. The company is not receiving proceeds from this specific offering, which is for resale by existing stockholders.

Positives

• Acquired all U.S. rights to Ameluz and RhodoLED and associated patents from Biofrontera AG, potentially simplifying operations and increasing control over the primary product.
• Reduced Ameluz transfer price from 50% to 25% for 2024-2025, with stepwise increases to 35% for certain indications starting 2026, which allows financing R&D activities and commercial growth.
• Took control of all clinical trials relating to Ameluz in the U.S. on June 1, 2024, enabling more effective cost management and direct oversight of trial efficiency.
• FDA approved the new, larger RhodoLED XL lamp in late October 2021, allowing for the illumination and treatment of larger areas.
• FDA approved a new Ameluz formulation (lacks propylene glycol, reduces contaminants) to be implemented in 2024, with a patent application filed for potential protection until 2043.
• FDA approved an increase in the maximally approved dosage of Ameluz from one to three tubes per treatment in October 2024, providing greater flexibility and efficiency for healthcare professionals.
• Ameluz PDT is highly effective, with patients experiencing up to 91% clearance after one or two treatments with limited or no scarring.
• Xepi, a licensed product for impetigo, has no known antibiotic resistance.

Negatives

• The company will not receive any proceeds from the sale of shares by the Selling Stockholders in this offering.
• Sole source of revenue is from licensed products, posing a significant risk if license agreements are terminated or obligations are not met.
• Certain important patents for Ameluz expired in 2019, increasing the risk of generic competition and potential significant price reductions or market share loss.
• Reliance on single or limited unaffiliated contract manufacturers for Ameluz poses supply chain risks.
• Third-party manufacturing delays have impacted the re-commercialization timeline and revenue generation for the Xepi product line.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of operating losses and anticipates continued losses, with no assurance of sustained profitability.
• Risk of delisting from Nasdaq if compliance with applicable listing standards is not maintained.
• Future sales and issuances of common stock from outstanding warrants, Series B Preferred, Series C Preferred, and convertible notes could result in substantial dilution to existing stockholders.
• Warrants are accounted for as a liability, with changes in fair value reported in earnings, which may cause significant quarterly fluctuations and adversely affect the market price of common stock.

Risks

• Failure to comply with obligations under license agreements or termination of such agreements could lead to loss of critical license rights.
• Expiration of important Ameluz patents in 2019 may lead to generic competition, potentially forcing price reductions and significant market share loss.
• Business substantially depends on Ameluz; inability to successfully obtain and maintain regulatory approvals or reimbursement for existing and additional indications could materially harm the business.
• Reliance on single or limited unaffiliated contract manufacturers for Ameluz poses risks of supply shortages, quality issues, or non-compliance with manufacturing regulations.
• Involvement in lawsuits to defend or enforce patents related to licensed products could be expensive, time-consuming, and unsuccessful.
• Lack of control over sourcing, manufacturing, and regulatory approvals for licensed products, which are controlled by existing and future collaborators, could adversely affect strategy implementation.
• Inability to effectuate a timely sale of Xepi or receive consideration in excess of its carrying value.
• Limited or unavailable insurance coverage and medical expense reimbursement for licensed products could hinder sales.
• Healthcare legislative changes may have a material adverse effect on business and results of operations.
• Significant competition from other pharmaceutical and medical device companies, including existing treatments like cryotherapy, could negatively impact operating results.
• Uncertainty of research and development efforts to enhance the commercial success of products.
• Substantial doubt about the company's ability to continue as a going concern.
• History of operating losses and anticipation of continued operating losses, with no assurance of sustained profitability.
• Failure to obtain additional financing may hinder marketing efforts for Ameluz or commercialization of other licensed products.
• Failure to maintain an effective system of internal controls may impair the ability to produce timely and accurate financial statements and erode investor confidence.
• Failure to maintain compliance with Nasdaq listing standards could result in delisting of common stock and publicly-traded warrants.
• Delay or termination of planned clinical trials for expanding Ameluz indications would result in unplanned expenses and adversely impact developmental activities and commercial prospects.
• Outstanding warrants, Series B Preferred, Series C Preferred, and Notes, if exercised or converted, could substantially increase the number of shares eligible for future resale and result in dilution.
• Future sales and issuances of common stock or rights to purchase common stock, including pursuant to equity incentive plans, could result in additional dilution and cause the stock price to decline.
• Charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of stock.
• Exclusive forum provisions in the amended and restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Warrants accounted for as a warrant liability and recorded at fair value with changes reported in earnings may have an adverse effect on the market price of common stock due to volatility.

Future Outlook

The company aims to expand Ameluz sales in the U.S. and position it as the standard of care by focusing on new customer acquisition and growth within the existing customer base. It plans to leverage future approvals and label extensions for its licensed portfolio, including taking over responsibility for Ameluz clinical development. The company will continue to opportunistically invest in R&D to improve BF-RhodoLED lamps and strategically manage its portfolio, including potential divestitures like Xepi and adding complementary products or services. Clinical trials are ongoing for Ameluz in superficial basal cell carcinoma (CSR expected Q2 2025), moderate to severe acne (last-patient-out expected Q3 2025, CSR expected Q3 2026), and actinic keratosis on trunk & extremities (recruitment near completion, last-patient-out expected Q1 2026, CSR expected Q3 2026). Plans are in place to start enrollment for Ameluz trials in combination daylight and conventional PDT and squamous cell carcinoma in situ in 2026. A new Ameluz formulation will be implemented in all U.S. productions starting in 2024, with potential patent protection until 2043.

Management Comments

• Our principal objective is to improve patient outcomes by increasing the sales of our licensed products.
• By executing these three strategic objectives, we will fuel company growth, deepen our trusted relationships in the dermatology community, and above all, help patients live healthier, more fulfilling lives.

Industry Context

Biofrontera operates within the dermatology biopharmaceutical market, with a primary focus on photodynamic therapy (PDT) for pre-cancerous skin lesions (actinic keratoses, AK) and, to a lesser extent, topical antibiotics for impetigo. The AK market is substantial, estimated at $4 billion annually, but PDT currently holds a small 2% market share, with cryotherapy dominating at 86% and topical medications at 12%. The company's strategy to acquire full U.S. rights to Ameluz and RhodoLED, coupled with the divestiture of Xepi, indicates a strategic consolidation around its core PDT business. This move aims to enhance control over product development and commercialization, potentially allowing for more aggressive market penetration against established, less effective treatments like cryotherapy, particularly for larger lesion areas. The company faces competition in the PDT space from products like Levulan and Blu-U.

Comparison to Industry Standards

• Ameluz PDT demonstrates high efficacy with up to 91% clearance after one or two treatments, and limited or no scarring, positioning it as a strong alternative to traditional treatments.
• Cryotherapy, the most common AK treatment (estimated 86% market share), is noted as potentially less effective and may leave scarring, suggesting Ameluz PDT offers a superior patient outcome in these aspects.
• Topical medications, comprising approximately 12% of the AK market, require multiple applications over several weeks, whereas Ameluz PDT is a two-step process, potentially offering greater convenience and compliance.
• The company's primary competitor in the PDT space is Levulan and its associated light, Blu-U, though specific comparative performance metrics against these competitors are not detailed in the document.

Corporate Governance

Legal Proceedings

• The Biofrontera Group has been involved in lawsuits to defend or enforce patents related to licensed products and may become involved in similar suits in the future, which could be expensive, time-consuming, and unsuccessful.
• The company may be the target of securities litigation in the future due to stock price volatility, which could result in substantial costs and divert management's attention.

Related Party Transactions

• On June 30, 2025, the company entered into an agreement with Biofrontera AG and certain of its subsidiaries (a related party) to acquire all U.S. rights to Ameluz and RhodoLED and the associated patents.
• As part of the acquisition agreement, the company issued 3,019 shares of Series D Convertible Preferred Stock to Biofrontera AG.
• Biofrontera AG holds approximately 3.9% of the outstanding shares of the company's common stock as of July 15, 2025.
• Intercompany Services Agreement dated January 1, 2016, between the company, Biofrontera AG, Biofrontera Pharma GmbH, and Biofrontera Bioscience GmbH.
• Amended Settlement Allocation Agreement dated March 31, 2022, between the company and Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, and Biofrontera Neuroscience GmbH.
• Settlement Agreement dated April 11, 2023, and Amendment No. 1 dated October 12, 2023, between Biofrontera Inc., its executive officers and directors, and Biofrontera AG.

Stakeholder Impact

• Shareholders face potential significant dilution from the conversion of various preferred stock, notes, and warrants, and the stock price may be volatile. Gains on investment will likely depend on price appreciation as the company does not intend to pay dividends. Anti-takeover provisions may limit favorable acquisition opportunities.
• Customers (healthcare providers and patients) may benefit from increased flexibility in Ameluz treatment due to higher approved dosage and larger lamp, as well as potential new indications and an improved product formulation.
• Employees may benefit from equity incentive plans, and the management team appears stable, focusing on strategic growth.
• Licensors, particularly Biofrontera AG, have restructured their relationship with the company, moving to a royalty model and divesting U.S. rights to Ameluz, while Ferrer is working to resolve manufacturing delays for Xepi.
• Creditors holding the 10.0% Senior Secured Convertible Notes have a claim on the company's assets and the potential for conversion into common stock.

Next Steps

• Finalize the definitive asset transfer agreement to effect the acquisition of all U.S. rights to Ameluz and RhodoLED and associated patents.
• Obtain stockholder approval for the issuance of Series D Preferred Stock and all common stock issuable upon conversion, as required under Nasdaq listing rules.
• Ferrer to complete the qualification of a new contract manufacturer for Xepi.
• Close the divestiture transaction for the Xepi product line during the second half of 2025.
• Receive the Clinical Study Report (CSR) for the Ameluz Superficial basal cell carcinoma clinical trial (expected Q2 2025).
• Reach last-patient-out of treatment phase for the Ameluz Moderate to severe acne trial (expected Q3 2025) and receive its CSR (expected Q3 2026).
• Reach last-patient-out of treatment phase for the Ameluz Actinic Keratosis (Trunk & extremities) trial (expected Q1 2026) and receive its CSR (expected Q3 2026).
• Begin enrollment for Ameluz Actinic Keratosis (combination daylight and conventional PDT) and Ameluz Squamous cell carcinoma in situ clinical trials (planned 2026).
• Implement the new formulation of Ameluz in all U.S. productions starting in 2024.
• Continue opportunistically investing in research and development activities to improve the capabilities of BF-RhodoLED lamps.

Key Dates

Recommendation

Keywords

Biofrontera, Ameluz, RhodoLED, Photodynamic Therapy, Actinic Keratosis, Dermatology, Biopharmaceutical, SEC Filing, S-1, Preferred Stock, Common Stock, Nasdaq, Clinical Trials, Xepi, Impetigo, Corporate Governance, Risk Management, Capital Raise, Dilution